UPDATED – 2022 Safety Protocols

CHI has instituted mandatory health and safety protocols for all in-person participants. We are excited to bring our community back together in 2022, with trust and safety as our top priorities. All in-person participants are required to:

Provide proof of full vaccination against COVID-19. You will be asked to present your vaccination card (or a photo of it) at registration.
Have a negative COVID-19 test result from an FDA-authorized, a WHO-authorized, or European authorized over-the-counter antigen test within 24 hours prior to arriving at the event. You will be asked your results at registration.

Conference Programs

Monday, 23 May & Tuesday AM, 24 May

Targeting the Tumour Microenvironment

Immuno-Oncology Therapeutic Development

Tuesday PM, 24 May & Wednesday, 25 May

T Cell-Based Cancer Immunotherapy

Bispecific and Multi-Specific Antibody Therapeutics

About the Immuno-Oncology Summit Europe

CHI’s Sixth Annual Immuno-Oncology Summit Europe returns to London’s Canary Wharf for three packed days of science and technology, discussion and networking, with coverage of recent advances in the development of promising immuno-oncology treatments. The event is comprised of three conference programs that cover therapeutic categories; T-Cell and related Cellular Therapeutics, Bi-specific Antibodies and Therapies targeting the Tumour Microenvironment, while a fourth program covers strategies for Therapeutic Development, including Predictive Biomarkers, Preclinical studies and Translational Studies. Clinical results and combination therapies will also be highlighted.

VIEW AGENDAS